Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.

Subodh VermaMohammed Al-OmranLawrence A LeiterC David MazerSøren RasmussenHans A SaevereidMaria Sejersten RipaMarc P Bonaca

Published in: Diabetes, obesity & metabolism (2022)

Both liraglutide and semaglutide reduce MACE with consistent CV efficacy regardless of PAD status.

Keyphrases